Tilray Stock Pops on New Trump-Driven Cannabis Hopes. Should You Chase the Rally?
Tilray shares rally as Trump urges the DOJ to quickly reclassify cannabis as a Schedule III drug. Options pricing suggests TLRY stock could rip higher through mid-September.
Barchart ·